Expert Interview
Digging into Axsome's AXS-07 for the acute treatment of migraine
Ticker(s): AXSMInstitution: Veteran's Administration & Avidity Biosciences
- Neurologist who treats 180-200 migraine patients over a 6 month period.
- Fellowship trained at UCLA in movement disorders
- While at Penn State University, founded a laboratory studying neurodegeneration and currently working in clinical development for Avidity.
Roughly how many patients with migraine do you currently manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for AXX-07?
Added By: c_adminPlease describe the treatment algorithm that you utilize
Added By: user1ae2bf5fHas your triptan usage up front been impacted at all by availability of oral CGRP's, or are triptans still preferred predominantly first line
Added By: user1ae2bf5fOverall view of clinical data on AXS07 in terms of safety and efficacy
Added By: user1ae2bf5fDo you currently prescribe triptans with meloxicam or other NSAIDS as an option for patients not sufficiently helped by triptans?
Does AXS07 data encourage you to use NSAID + triptan more often?
Added By: user1ae2bf5fDoes AXS07 have a market opportunity when generic components of the combo are available separately very cheaply?
Added By: user1ae2bf5fSparing of need for rescue medications shown in INTERCEPT trial with AXS07 - Is this a meaningful result?
Added By: user1ae2bf5fIs formulation of AXS07 with both components together (and MOSEIC meloxicam) leading to more rapid onset of benefit something you consider credible? Or not likely?
Added By: user1ae2bf5fIs there a pricing tier that Axsome could set for AXS07 where although it's more expensive than the generic components separately, they could create an opportunity for the drug by coming in significantly lower than where Treximet was priced?
Added By: user1ae2bf5fIs AXS07 an analogous situation to Treximet?
Did you ever use Treximet at all?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
